Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
Autor: | Raul Franco, María Florencia Coronel, Juan Fló, Norma Alejandra Chasseing, Ricardo A. López, David L. Horn, Andrés Hernando-Insúa, Steven M. Opal, Alejandro D. Montaner, Fernanda Elías, Juan M. Rodríguez, Victoria Lux-Lantos, Jorge Zorzopulos |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Histology CIENCIAS MÉDICAS Y DE LA SALUD Immunohomeostasis Inflammation Review Imt504 Sepsis 03 medical and health sciences Immune system In vivo Genetics medicine Molecular Biology Genetics (clinical) IMT504 business.industry Regeneration (biology) Mesenchymal stem cell Mesenchymal Stem Cells Patología Cell Biology purl.org/becyt/ford/3.1 [https] Bioquímica y Biología Molecular medicine.disease Molecular biology Clinical trial Medicina Básica 030104 developmental biology Immunoprotection Neuropathic pain Immunology Immunoregeneration Mesenchymal stem cells purl.org/becyt/ford/3 [https] medicine.symptom business |
Zdroj: | World Journal of Stem Cells CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET |
Popis: | The immune responses of humans and animals to insults (i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged pro-inflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell (MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy. Fil: Zorzopulos, Jorge. Immunotech; Argentina Fil: Opal, Steven M.. Memorial Hospital of Rhode Island; Estados Unidos. Alpert Medical School; Estados Unidos Fil: Hernando Insúa, Andrés. Fundación Pablo Cassara; Argentina Fil: Rodriguez, Juan M.. Fundación Pablo Cassara; Argentina Fil: Elías, Fernanda. Fundación Pablo Cassara; Argentina Fil: Fló, Juan. Immunotech; Argentina Fil: López, Ricardo A.. Imunotech; Argentina Fil: Chasseing, Norma Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Lux, Victoria Adela R.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Coronel, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Franco, Raul. Imunotech; Argentina Fil: Montaner, Alejandro D. Fundación Pablo Cassara; Argentina Fil: Horn, David L. David Horn Llc; Estados Unidos |
Databáze: | OpenAIRE |
Externí odkaz: |